SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, and ZenBio Inc., a leading provider of advanced cell-based solutions and services, are partnering to produce three-dimensional human tissues for drug discovery and advanced tissue therapies.
ZenBio will provide unique, validated cellular inputs for use by Organovo with its NovoGen™ bioprinting technology to enable the generation of living, three-dimensional tissues that reproduce the architectural and functional features of tissues inside the human body. The resulting 3D tissue models may lead to advances in medical research, drug discovery and development as well as direct therapies and transplantation.
"ZenBio is a highly respected provider of human cells, which are key inputs to our 3D tissue models," said Keith Murphy , Chairman and Chief Executive Officer at Organovo. "Together, we can create new tissues and disease models that offer greater preclinical predictive value for drug discovery, and will fill unmet needs for medical research and surgical therapies."
"At ZenBio, we recognize the shift towards 3D cell culturing platforms for assay development. This is especially true for potency assays, which are a regulatory requirement for tissue engineered and regenerative medicine therapeutics. Additionally, our commercial and academic clients are continually seeking 3D cell culturing products as a bridge towards in vivo studies. Organovo's technology has the ability to satisfy the regulatory, academic, and commercial needs for 3D cell culturing," said Dr. John W. Ludlow , Executive Director of Regenerative Medicine at ZenBio Inc.
About Organovo Holdings, Inc.
Organovo designs and creates functional,
|SOURCE Organovo Holdings, Inc.|
Copyright©2012 PR Newswire.
All rights reserved